Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Silver. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28236202 | 0.87 | KDM4E (0.53) | KDM4EHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL793724 | 0.87 | MEN1 (0.65) | KDM4EHPGDLMNASMN1; SMN2PTGER1 | |
| SCHEMBL14660694 | 0.85 | MEN1 (0.63) | KDM4EHPGDLMNASMN1; SMN2PTGER1 | |
| Hydrochloric Acid SCHEMBL514496 | 0.85 | MEN1 (0.63) | KDM4EHPGDLMNASMN1; SMN2PTGER1 | |
| SCHEMBL18993390 | 0.84 | KDM4E (0.69) | KDM4EHPGDPTGESLMNASMN1; SMN2 | |
| SCHEMBL2343079 | 0.84 | MAOB (0.59) | KDM4EHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL514495 | 0.84 | GLRA1 (0.65) | KDM4EHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL2787229 | 0.83 | SMN1; SMN2 (0.51) | KDM4EHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL794412 | 0.83 | KMT2A (0.62) | KDM4EHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL2338199 | 0.81 | HPGD (0.76) | KDM4EHPGDLMNASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189840-B1 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | KEMPHARM INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20190142815-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | ALTER DOMUS (US) LLC | 2019-05-16 | — | — | US | disclosed |
| US-10231960-B2 | Methylphenidate-prodrugs, processes of making and using the same | KEMPHARM INC. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3189840-A1 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-2736510-B1 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | KEMPHARM INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170049765-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMMAVE THERAPEUTICS SA (CH) | 2017-02-23 | — | — | US | disclosed |
| US-9453037-B2 | Methylphenidate-prodrugs, processes of making and using the same | KEMPHARM, INC (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150266911-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMMAVE THERAPEUTICS SA (CH) | 2015-09-24 | — | — | US | disclosed |
| US-9079928-B2 | Methylphenidate-oxoacid conjugates, processes of making and using the same | KEMPHARM, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140243291-A1 | METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME | COMMAVE THERAPEUTICS SA (CH) | 2014-08-28 | — | — | US | disclosed |
| EP-2736510-A2 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013016668-A2 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | KEMPHARM INC. (US) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243291-A1 | METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME | COMT, PNMT, SLC6A3 | KDM4E 504/4885HPGD 1369/4885PTGES 1582/4885 |
| US-20170049765-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | KDM4E 475/4885HPGD 1173/4885PTGES 1226/4885 |
| US-20150266911-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | KDM4E 475/4885HPGD 1173/4885PTGES 1226/4885 |
| US-20190142815-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | KDM4E 475/4885HPGD 1173/4885PTGES 1226/4885 |
| US-10231960-B2 | Methylphenidate-prodrugs, processes of making and using the same | COMT, TPMT, PNMT | KDM4E 475/4885HPGD 1173/4885PTGES 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.